ArticleLasers in medical science2025
Potential of neodymium laser in treatment of extensive telangiectasias on the face.
Article in Lasers in medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTelangiectasia is a persistent expansion of the superficial vessels of the skin. They do not cause subjective discomfort to patients. The purpose of the treatment of telangiectasia is to eliminate the cosmetic defect. Percutaneous laser coagulation is a modern method of treating telangiectasias. CASE REPORT: A 50-year-old male patient underwent 2 sessions of laser obliteration of telangiectasias using an ND: YAG laser with a wavelength of 1064 nm, a pulse duration of 650 microseconds, a spot diameter of 2 mm, and an energy flux density of 127-223 J/cm
conclusionND: YAG laser with a wavelength of 1064 nm, a pulse duration of 650 microseconds using a working spot diameter of 2 mm and an energy flux density in the range of 127-223 J/cm2 showed a high efficiency and safety profile in the obliteration of telangiectasias in a patient with extensive facial lesions.
Indexed as
Identifiers
40257683What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.